Other safety alerts
|
| |
| Singapore: Recommendations to avoid use of glibenclamide in the elderly and renal-impaired |
| |
The Health Sciences Authority (HSA) had conducted a benefit-risk assessment of glibenclamide in consultation with endocrinologists and its Product Vigilance Advisory Committee (PVAC), prompted by reports of a disproportionately higher number of hospitalisation cases due to hypoglycaemia associated with glibenclamide as compared to other sulfonylureas (SUs). Based on the review, HSA would like to advise healthcare professionals that the use of glibenclamide should be avoided in elderly patients and those with renal impairment, as these patients are more susceptible to severe and recurrent hypoglycaemia.
After in-depth review and consultation with endocrinologists and its PVAC, HSA's assessment and recommendations are as follows:
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/publish/hsaportal/../recommendations_to.html
In Hong Kong, there are 30 registered pharmaceutical products containing glibenclamide. All the products are prescription only medicines. Related news has been released by HSA and was posted on the Drug Office website on 5 December 2013. DH will keep vigilant on any safety updates of the drug and actions taken by other overseas regulatory authorities for consideration of any action deemed necessary.
Ends/ Saturday, January 4, 2014
Issued at HKT 14:30
|
| |
|
